Anonymous ID: e5646f Jan. 18, 2019, 7:33 p.m. No.4813996   🗄️.is 🔗kun   >>4023

Taibbi: Has The Government Legalized Secret Defense Spending?

 

While a noisy Supreme Court fight captivated America last fall, an obscure federal accounting body quietly approved a system of classified money-moving…

 

October 4th, 2018, was a busy news day. The only thing that did not make the news was an announcement by a little-known government body called the Federal Accounting Standards Advisory Board — FASAB — that essentially legalized secret national security spending. The new guidance, “SFFAS 56 – CLASSIFIED ACTIVITIES” permits government agencies to “modify” public financial statements and move expenditures from one line item to another. It also expressly allows federal agencies to refrain from telling taxpayers if and when public financial statements have been altered. The FASAB ruling adds a new and confusing wrinkle to what little we know about levels of spending in the intelligence community. Officially, the fiscal year 2019 appropriation is $81.1 billion, which breaks down to $59.9 billion for the National Intelligence Program, along with $21.2 billion for the Military Intelligence Program.

 

The story of openly secret budgets really began in 1949, with the passage of the Central Intelligence Agency Act. The law exempted the newly christened spy agency from public financial disclosure. The CIA Act was a radical departure from the Constitution, which is clear about public accounting (emphasis mine): “No Money shall be drawn from the Treasury, but in Consequence of Appropriations made by Law; and a regular Statement and Account of the Receipts and Expenditures of all public Money shall be published from time to time.”

 

The CIA Act created a blunt constitutional carve-out. “The sums made available to the Agency may be expended without regard to the provisions of law and regulations relating to the expenditure of Government funds,” the law read. “For objects of a confidential, extraordinary, or emergency nature, such expenditures to be accounted for solely on the certificate of the Director…” In other words, while other government agencies had to account for their expenses, the word of the CIA director was good enough when it came to what they’d spent and why. In a few accidental disclosures in the Fifties, CIA expenses appeared as Department of Defense line items, despite the fact that the CIA is not a Defense agency.

 

On November 15th, 2018, however, the Department of Defense failed its first audit, which was conducted by 1,200 auditors. This was after 26 years of what Sen. Chuck Grassley (R-IA) called “hard-core foot-dragging. We failed the audit, but we never expected to pass it,” Deputy Secretary of Defense Patrick Shanahan said at the time. That the Pentagon failed its audit was no surprise. There had already been significant hints that even the supposedly legal version of defense budgeting was an indecipherable morass.

 

On the day before 9/11, for instance, then-Defense Secretary Donald Rumsfeld announced that, according to some estimates, “we cannot track $2.3 trillion in transactions.” The following day’s events obviously distracted the media from that shock announcement. In 2015, the Office of the Inspector General found the Army alone — which had a budget of $122 billion that year — had $6.5 trillion in “yearend adjustments” they could not “adequately support.” Skidmore recalls being dumbfounded by the numbers. Outside auditors found that just one Pentagon outfit, the Defense Logistics Agency, could not account for over $800 million in construction transactions. Despite these and other objections, on October 4th of last year, FASAB issued a news release about SFFAS 56. The text of the new rule strongly resembled the original proposal. In plain English, the new guidance allowed federal agencies to “modify” public financial statements, with essentially a two-book system. Public statements would at best be unreliable, while the real books would be audited in “classified environment[s]” by certain designated officials.

 

One thing is certain: the taxpayer who opens up a federal financial statement expecting to find correct numbers will no longer be sure of what he or she is reading. Bluntly put, line items in public federal financial statements may now legally be, for lack of a better word — wrong. Given the government’s track record in failing to force transparency out of the Pentagon, it’s hard to have a lot of confidence answers will be forthcoming. “The White House and Congress just opened a pipeline into the back of the US Treasury,” Catherine Austin Fitts wrote, “and announced to every private army, mercenary and thug in the world that we are open for business.

Anonymous ID: e5646f Jan. 18, 2019, 7:35 p.m. No.4814023   🗄️.is 🔗kun

>>4813996

A legalized dualistic system for public financial reporting would therefore just be the latest blow to federal transparency, but it would be a big one. It would be nice to get a few answers before paying taxes into a black box becomes a permanent feature of American life…

 

https://www.zerohedge.com/news/2019-01-18/taibbi-has-government-legalized-secret-defense-spending

 

Sorry for early trigger, hit the wrong button.

Anonymous ID: e5646f Jan. 18, 2019, 7:47 p.m. No.4814181   🗄️.is 🔗kun   >>4249

This Startup Will Let You Have A Younger Person's Blood For $8,000

 

A graduate of Stanford University - incubator of such famous blood-linked companies as Theranos - has launched a controversial start-up company, called Ambrosia, that will, for a generous fee, replace the blood of older people with that of younger donors in yet another attempt to conquer aging. Business Insider reported on the company first, while admitting there is little to no evidence that the procedure actually works. But that hasn’t stopped Amborisa creator Jesse Karmazin, from accepting payments via PayPal for the procedure: he is charging $8,000 for one liter of young blood and $12,000 for two liters. Karmazin, who isn’t a licensed medical practitioner, told reporters last year that he had hoped to open his first clinic in New York City by the end of 2018. New York City has eluded him and instead he has opened locations in places like Los Angeles, San Francisco, Tampa and Houston.

 

Just like Theranos, the company also performed its own clinical trial to figure out what the effects of blood swapping would be. These results haven’t been made public, but Karmazin has called them "really positive". And despite the fact that there hasn’t been any evidence that it works, Ambrosia is allowed to continue under the FDA‘s approval of blood transfusions. Further propelling the idea forward is the significant amount of interest it has received. After putting up its first website in September, the company reportedly got 100 inquiries (mostly from very rich people) about how to get the treatment. The company's chief operating officer at the time has since left the company in January, leaving its founder as its only employee.

 

As of the fall last year, the company had performed the procedure on about 150 people who ranged in age from 35 to 92. 81% of those people participated in the company's clinical trial. The trial gave patients one and a half liters of plasma from a donor between the ages of 16 and 25 and was conducted with David Wright, a physician who has his own intravenous blood therapy center in California. Trial participants paid for their infusions and the metrics recorded in the study have not been publicly released. "The trial was an investigational study. We saw some interesting things, and we do plan to publish that data. And we want to begin to open clinics where the treatment will be made available," the company's COO said… several months before he left.

 

And while there has been no evidence yet that there is any efficacy, normal blood transfusions still often save lives. When somebody has undergone surgery or been in a traumatic accident, transfusions can be one of the safest life-saving procedures available. Clinicians perform about 14.6 million transfusions per year, which equates to about 40,000 of them happening every day. But the problem is that the science around young blood replacing old blood to fight aging simply doesn’t exist in robust form. For instance, the results of a study that used young blood in older humans to try to counteract Alzheimer’s disease were published this month in JAMA Neurology. While the study was described as "safe, well tolerated and feasible" the authors of it were reluctant draw conclusions about potential benefits. But that hasn't stopped Karmazin from doing so; he said in 2017: "Some patients got young blood, and others got older blood, and I was able to do some statistics on it, and the results looked really awesome. And I thought this is the kind of therapy that I'd want to be available to me."

 

ttps://www.zerohedge.com/news/2019-01-17/startup-will-let-you-have-younger-persons-blood-8000

Anonymous ID: e5646f Jan. 18, 2019, 8:01 p.m. No.4814363   🗄️.is 🔗kun   >>4381

>>4814249

Sounds like they are working hard to normalize this..in addition to that..this individual isn't even a physician. How could that be legal or even authorized..Doesn' it require special handling?